Finally, we identified six compounds (1S,3R-RSL-3, ML210, ML162, RITA, LY2606368, and panobinostat) as potential therapeutic agents for CRC patients with high ACACB expression, which needs to be further verified. This evidence concerns the gene ACACB and colorectal carcinoma.